New radiation drug targets tough cancers in early trial

NCT ID NCT07006727

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 32 times

Summary

This early-stage study tests a new drug that delivers radiation directly to cancer cells with a protein called DLL3. It is for adults with advanced lung, prostate, or gut cancers that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Corewell Health William Beaum Hosp

    RECRUITING

    Royal Oak, Michigan, 48073-6769, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Fred Hutchinson Cancer Research Center

    RECRUITING

    Seattle, Washington, 98109-1024, United States

    Contact Email: •••••@•••••

    Contact

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact Email: •••••@•••••

    Contact

  • Novartis Investigative Site

    RECRUITING

    Montreal, Quebec, H3T 1E2, Canada

  • Novartis Investigative Site

    RECRUITING

    Seoul, 03080, South Korea

  • University Of Iowa

    RECRUITING

    Iowa City, Iowa, 52242, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.